No Data
Zhitong Hong Kong Stocks Early Insight | Yu Liang resigns as Chairman of the Board of Directors of Vanke (02202), and Xin Jie, Chairman of Shenzhen Metro Group, takes over.
According to the announcement from China Vanke Co.,Ltd., Shenzhen Metro Chairman Xin Jie has been appointed as the Chairman of the Board of Directors of China Vanke Co.,Ltd., while Yu Liang, who has resigned from the position of Chairman of the Board, will serve as the First Executive Vice President of China Vanke Co.,Ltd.
Hong Kong Stock Announcement Gold Mining | CSTONE PHARMA-B reaches a strategic cooperation with SteinCares regarding sugar-lowering monoclonal antibody in the Americas.
CONCORD NE (00182) intends to sell 100% equity of Taiming Company to Shadian for 0.636 billion yuan; CHINA VANKE (02202) intends to transfer the sales rights and equity for the Hongshu Wan project.
SH PHARMA (601607.SH): plans to invest 1 billion yuan to establish a merger and acquisition Fund.
On January 27, Gelonghui reported that SH PHARMA (601607.SH) announced its plan to participate as one of the limited partners in the establishment of a Merger and Acquisition Fund. The fund is expected to raise 5.01 billion yuan, with SH PHARMA committing 1 billion yuan of its own funds. The symbol fund will focus on the overall strategic development of the Shanghai Biomedical industry, aiming to connect globally and serve Shanghai's functional positioning, and strive to promote Shanghai's capacity to attract and gather international and domestic Biomedical industry innovative resources, collaborate with key areas of the Shanghai Biomedical industry, focus on the segments that significantly support the development of Shanghai’s Biomedical sector, and promote the construction of Biomedical research and development in Shanghai.
HAITONG INT'L: Maintains SH PHARMA "Outperform the Market" rating, with the Target Price raised to HKD 14.39.
HAITONG INT'L released a research report stating that it slightly lowered the revenue forecast for SH PHARMA (02607) for 2024 to 27.73 billion yuan, and slightly raised the revenue forecast for 2025/26 to 30.08/32.4 billion yuan, to reflect the impact of acquisitions and Huang Pharmaceutical; it slightly lowered theNet income forecast for 2024/25/26 to 4.8/5.4/5.7 billion yuan, respectively. The bank uses a cash flow discount model and cash flows from FY25-FY33 for valuation. Based on a WACC of 6.2%, a perpetual growth rate of 3%, and a 60% discount of Hong Kong stocks to A-shares (all unchanged), the corresponding Target Price is raised by 4.1.
[Brokerage Focus] HAITONG INT'L maintains SH PHARMA (02607) outperform rating, expects a 6.5% year-on-year revenue growth for the full year 2024.
Jinwu Financial News | HAITONG INT'L issued a research report indicating that SH PHARMA (02607) is expected to achieve revenue of 277.3 billion yuan in 2024, up 6.5% year-on-year. By Sector: Pharmaceutical Commerce Sector (Distribution + Retail): The bank expects that in 2024, Pharmaceutical Commerce will achieve revenue of 252.7 billion yuan, an increase of 8.0% year-on-year. Among this, the expected revenue from the pharmaceutical distribution business is 252.9 billion yuan (including inter-segment transactions), growing by 8.2% year-on-year, mainly due to the revenue increments from CSO business, import agency business, and SPD (Logistics management) business. Pharmaceutical Industry Sector: The bank expects that in 2024, the pharmaceutical industry...
SH PHARMA (601607.SH): Ursodeoxycholic acid capsules have been approved for production.
On January 22, Gelonghui reported that SH PHARMA (601607.SH) announced that its holding subsidiary, Changzhou Pharmaceutical Factory Co., Ltd. (referred to as "Changzhou Pharmaceutical Factory"), has received the "Pharmaceutical Registration Certificate" (Certificate No: 2025S00209) issued by the National Medical Products Administration for ursodeoxycholic acid capsules (specification: 250mg; referred to as "the pharmaceutical"). This pharmaceutical has been approved for production. Ursodeoxycholic acid capsules are primarily used to treat cholesterol gallstones in the gallbladder—specifically, stones that are penetrable by X-rays, and the gallbladder must have normal contraction function; cholestatic liver disease (e.g., primary biliary cirrhosis); and bile reflux gastritis.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
